, Tracking Stock Market Picks
Enter Symbol:
Micromet, Inc. (MITI) [hlAlert]

up 275.08 %

Micromet, Inc. (MITI) rated Buy by Merriman Curhan Ford

Posted on: Wednesday,  Mar 25, 2009  8:25 AM ET by Merriman Curhan Ford

Merriman Curhan Ford rated Buy Micromet, Inc. (NASDAQ: MITI) on 03/25/2009, when the stock price was $2.93. Since
then, Micromet, Inc. has gained 275.09% as of 03/07/2012's recent price of $10.99.
If you would have followed this Merriman Curhan Ford's recommendation on MITI, you would have gained 275.08% of your investment in 1078 days.

Micromet, Inc. (Micromet) is a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. Four of the Company's antibodies are in clinical trials, while the remainder of its product pipeline is in pre-clinical development. The Company?s BiTE antibody blinatumomab, known as MT103, is being evaluated in a phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase I clinical trial for the treatment of patients with non-Hodgkin?s lymphoma (NHL). A second BiTE antibody, MT110, is being tested in a phase I clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule (EpCAM), which is over-expressed in many solid tumors.

We occupy a unique niche among our investment banking peers: we offer our clients both traditional sell-side equity research and primary market research, and we focus on high-potential sectors such as CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. Our institutional and corporate clients get the best of both worlds: expertise from our analysts and access to experts through our Panel Intelligence platform.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/25/2009 8:25 AM Buy
as of 12/31/2009
1 Week down  -2.82 %
1 Month down  -4.39 %
3 Months down  -1.95 %
1 YTD up  122.86 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy